Advances in influenza virus-like particles bioprocesses

Durous, Laurent; Rosa‐Calatrava, Manuel; Petiot, Emma

doi:10.1080/14760584.2019.1704262

Cited by 20 publications

(24 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mammalian cells produce fewer of the VLPs with higher production cost compared with other systems [27]. In addition, HEK-293T cells and VeroE6 cells are adherent cells, and the upstream scale-up of culturing adherent cells is generally complex [28].…”

Section: Discussionmentioning

confidence: 99%

Production of SARS-CoV-2 Virus-Like Particles in Insect Cells

Xie

Zhu

et al. 2021

Vaccines

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) causes a serious threat to human health. Virus-like particles (VLPs) constitute a promising platform in SARS-CoV-2 vaccine development. In this study, the E, M, and S genes were cloned into multiple cloning sites of a new triple expression plasmid with one p10 promoter, two pPH promoters, and three multiple cloning sites. The plasmid was transformed into DH10 BacTMEscherichia coli competent cells to obtain recombinant bacmid. Then the recombinant bacmid was transfected in ExpiSf9TM insect cells to generate recombinant baculovirus. After ExpiSf9TM cells infection with the recombinant baculovirus, the E, M, and S proteins were expressed in insect cells. Finally, SARS-CoV-2 VLPs were self-assembled in insect cells after infection. The morphology and the size of SARS-CoV-2 VLPs are similar to the native virions.

show abstract

Section: Discussionmentioning

confidence: 99%

Production of SARS-CoV-2 Virus-Like Particles in Insect Cells

Xie

Zhu

et al. 2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…The VLP system is a promising platform for development of novel vaccines as alternatives for inactivated vaccines ( 58 – 60 ). Numerous vaccine candidates against different influenza subtypes were generated using the VLP platform ( 61 ).…”

Section: Discussionmentioning

confidence: 99%

“…However, for ultimately being proposed as a critical alternative to the traditional ovoculture vaccines in poultry, some challenges still need to be addressed for the VLP vaccine, mainly including optimization of the manufacturing processes to achieve higher antigen yields, minimization of the downstream processing cost of vaccine manufacturing as well as enhancements of broad protection against multiple variants and subtypes of influenza virus. Last, but not least, it is essential to establish the whole VLP production pipeline, from the upstream cell fermentation and antigen production to the downstream antigen quality-control and process, in vaccine enterprises for large-scale industrial production ( 58 ) and application of VLP vaccines in the field.…”

Section: Discussionmentioning

confidence: 99%

Single Dose of Bivalent H5 and H7 Influenza Virus-Like Particle Protects Chickens Against Highly Pathogenic H5N1 and H7N9 Avian Influenza Viruses

Peng

et al. 2021

Front. Vet. Sci.

View full text Add to dashboard Cite

Both H5N1 and H7N9 subtype avian influenza viruses cause enormous economic losses and pose considerable threats to public health. Bivalent vaccines against both two subtypes are more effective in control of H5N1 and H7N9 viruses in poultry and novel egg-independent vaccines are needed. Herein, H5 and H7 virus like particle (VLP) were generated in a baculovirus expression system and a bivalent H5+H7 VLP vaccine candidate was prepared by combining these two antigens. Single immunization of the bivalent VLP or commercial inactivated vaccines elicited effective antibody immune responses, including hemagglutination inhibition, virus neutralizing and HA-specific IgG antibodies. All vaccinated birds survived lethal challenge with highly pathogenic H5N1 and H7N9 viruses. Furthermore, the bivalent VLP significantly reduced viral shedding and virus replication in chickens, which was comparable to that observed for the commercial inactivated vaccine. However, the bivalent VLP was better than the commercial vaccine in terms of alleviating pulmonary lesions caused by H7N9 virus infection in chickens. Therefore, our study suggests that the bivalent H5+H7 VLP vaccine candidate can serve as a critical alternative for the traditional egg-based inactivated vaccines against H5N1 and H7N9 avian influenza virus infection in poultry.

show abstract

“…Influenza VLPs can be produced using different expression systems (mammalian, plant, or insect cell cultures) (Thompson et al, 2013). However, their production and purification processes still need further optimization in terms of yield, potency, and efficiency for VLPs to become a viable alternative to current vaccines (Durous et al, 2019).…”

Section: Virus-like Particlesmentioning

confidence: 99%

Downstream processing for influenza vaccines and candidates: An update

Carvalho

Peixoto

Carrondo

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

Seasonal and pandemic influenza outbreaks present severe health and economic burdens. To overcome limitations on influenza vaccines' availability and effectiveness, researchers chase universal vaccines providing broad, long-lasting protection against multiple influenza subtypes, and including pandemic ones.Novel influenza vaccine designs are under development, in clinical trials, or reaching the market, namely inactivated, or live-attenuated virus, virus-like particles, or recombinant antigens, searching for improved effectiveness; all these bring downstream processing (DSP) new challenges. Having to deal with new influenza strains, including pandemics, requires shorter development time, driving the development of faster bioprocesses. To cope with better upstream processes, new regulatory demands for quality and safety, and cost reduction requirements, new unit operations and integrated processes are increasing DSP efficiency for novel vaccine formats.This review covers recent advances in DSP strategies of different influenza vaccine formats. Focus is given to the improvements on relevant state-of-the-art unit operations, from harvest and clarification to purification steps, ending with sterile filtration and formulation. The development of more efficient unit operations to cope with biophysical properties of the new candidates is discussed: emphasis is given to the design of new stationary phases, 3D printing approaches, and continuous processing tools, such as continuous chromatography. The impact of the production platforms and vaccine designs on the downstream operations for the different influenza vaccine formats approved for this season are highlighted.

show abstract

Advances in influenza virus-like particles bioprocesses

Cited by 20 publications

References 134 publications

Production of SARS-CoV-2 Virus-Like Particles in Insect Cells

Production of SARS-CoV-2 Virus-Like Particles in Insect Cells

Single Dose of Bivalent H5 and H7 Influenza Virus-Like Particle Protects Chickens Against Highly Pathogenic H5N1 and H7N9 Avian Influenza Viruses

Downstream processing for influenza vaccines and candidates: An update

Contact Info

Product

Resources

About